Steven Cohen’s Royalty Pharma RPRX Stock Holding History

Steven Cohen’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.97M	Sell	106,549 -383,469	-78%	-$20M	0.01%	1636
2026 Q1	$23.5M	Sell	490,018 -44,288	-8%	-$1.94M	0.03%	717
2025 Q4	$20.6M	Buy	+534,306	New	+$20.4M	0.02%	865
2025 Q1	–	Sell	-249,003	Closed	-$7.89M	–	2468
2024 Q4	$6.35M	Sell	249,003 -277,630	-53%	-$7.36M	0.01%	871
2024 Q3	$14.9M	Buy	+526,633	New	+$14.6M	0.04%	510
2024 Q2	–	Sell	-521,200	Closed	-$15.8M	–	2356
2024 Q1	$15.8M	Sell	521,200 -647,600	-55%	-$19.1M	0.04%	541
2023 Q4	$32.8M	Buy	1,168,800 +440,600	+61%	+$12.1M	0.08%	300
2023 Q3	$19.8M	Buy	728,200 +198,000	+37%	+$5.88M	0.06%	406
2023 Q2	$16.3M	Sell	530,200 -88,600	-14%	-$3M	0.05%	441
2023 Q1	$22.3M	Buy	+618,800	New	+$22.9M	0.07%	324
2022 Q2	–	Sell	-1,892,900	Closed	-$73.7M	–	1606
2022 Q1	$73.7M	Buy	1,892,900 +1,556,800	+463%	+$61.1M	0.29%	80
2021 Q4	$13.4M	Buy	336,100 +277,000	+469%	+$10.8M	0.05%	433
2021 Q3	$2.14M	Buy	+59,100	New	+$2.3M	0.01%	784

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's RPRX Position: Q2 2026 in Review

Steven Cohen reduced its Royalty Pharma (RPRX) stake by 78% in Q2 2026, selling an estimated $20M and leaving 106,549 shares worth $5.97M. The position accounts for 0.01% of the portfolio, ranked #1636.

Steven Cohen first reported a position in RPRX in Q3 2021 and has held it in 13 quarters since. The position peaked at $73.7M in Q1 2022. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Steven Cohen held 106,549 shares of Royalty Pharma worth $5.97M as of Q2 2026.
Steven Cohen sold 383,469 Royalty Pharma shares in Q2 2026, an estimated $20M.
Royalty Pharma made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1636 holding.
Steven Cohen first reported a position in Royalty Pharma in Q3 2021 and has held it in 13 quarters since.
Steven Cohen's Royalty Pharma position peaked at $73.7M in Q1 2022.
640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.